Neostigmin

Neostigmin
(IUPAC) ime
	3- {[(dimetilamino)karbonil]oksi} -N,N,N-trimetilbenzenaminijum
Klinički podaci
Robne marke	Prostigmin
AHFS/Drugs.com	Monografija
Identifikatori
CAS broj	59-99-4
ATC kod	N07AA01 S01EB06 QA03AB93
PubChem	4456
DrugBank	DB01400
ChemSpider	4301
UNII	3982TWQ96G
KEGG	D08261
ChEBI	CHEBI:7514
ChEMBL	CHEMBL54126
Hemijski podaci
Formula	C12H19N2O2
Mol. masa	223,294 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1 ; Key: ALWKGYPQUAPLQC-UHFFFAOYSA-N
Farmakokinetički podaci
Bioraspoloživost	nepoznato
Metabolizam	Sporo se hidrolizuje posredstvom acetilholinesteraze
Poluvreme eliminacije	50–90 minuta
Izlučivanje	Nepromenjeni lek (do 70%)
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Neostigmin (Prostigmin, Vagostigmin) je parasimpatomimetik koji deluje kao reverzibilni inhibitor acetilholinesteraze.^[6]^[7]

Hemija uredi

Neostigmin, N,N,N-trimetil-meta-(dimetilkarbomoiloksi)-fenilamonijum metilsulfonat, koji se može smatrati pojednostavljenim analogom fizostigmina, se može formirati rekcijom 3-dimetulaminofenola sa N-dimetilkarbamoil hloridom. Time se formira dimetilkarbamat, čijom naknadnom alkilacijom koristeći dimetilsulfat nastaje željeno jedinjenje.^[8]

Vidi još uredi

Miotin

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. PMID 21059682.
↑ Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. PMID 18048412.
↑ 43. J.A. Aeschlimann, U.S. Patent 1.905.990 (1933).

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. PMID 21059682.

[7] Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. PMID 18048412.

[8] 43. J.A. Aeschlimann, U.S. Patent 1.905.990 (1933).

[6]

[7]

[1]

[2]

[3]

[4]

[5]

[8]